Editas Medicine EDIT reported a loss of 55 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus ...

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

So should Editas Medicine (NASDAQ:EDIT) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable compan ...

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has been given an average rating of “Hold” by the fourteen analysts that are currently covering the stock, MarketBeat reports. Two investment ...

Editas Medicine, Inc. announced that it will release its financial results and business updates for the fourth quarter and full year of 2024 on March 5, 2025, through a press release and SEC ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Editas Medicine (EDIT – Research Report) yesterday and set a price target of ...

Editas Medicine reports advancements in in vivo gene editing, financial results, and plans for upcoming development candidates by mid-2025. Editas Medicine, Inc. announced its progress in ...

The sequence contained a promising new genetic tool for modifying DNA, a CRISPR. Editas Medicine, a Massachusetts-based ...

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have received a consensus rating of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat reports.

On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in ...